PLEKHG2

Across TCGA pan-cancer cohorts, PLEKHG2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHG2 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLEKHG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHG2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where PLEKHG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.464	0.822	.030	9	view →
UCEC	DFS	Median	All	0.750	0.928	.009	8	view →
CCRCC	DFS	Quartile	All	0.849	1.000	.010	6	view →
PDAC	DFS	Quartile	III,IV	0.625	0.358	.027	3	view →
GBM	DFS	Median	All	0.270	0.467	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHG2–LUAD (OS)

Open the LUAD breakdown →